Neuronetics, INC 10-Q quarterly reports

Neuronetics reported increased revenue in Q2 2026 driven by its Greenbrook segment, but faces substantial doubt regarding its ability to continue as a going concern due to projected covenant non-compliance.

Neuronetics reports an 8% increase in Q1 2026 revenue to $34.5 million, driven by clinic services, but faces substantial doubt about its ability to continue as a going concern due to projected covenant breaches.

Neuronetics, Inc. reported a significant revenue increase in Q3 2025, primarily driven by the Greenbrook TMS acquisition, despite continued operating losses and gross margin compression.

Neuronetics reported a significant revenue increase in Q2 2025, primarily driven by the Greenbrook acquisition, though net losses persisted and gross margins declined.

Neuronetics' Q1 2025 revenue increased by 84% year-over-year, driven by the acquisition of Greenbrook, though net losses also widened.

Neuronetics' Q3 2024 results show a slight revenue increase year-over-year, alongside a strategic reorganization aimed at improving operational efficiency.

Neuronetics' Q2 2024 results show a decrease in revenue compared to the same period last year, alongside a significant increase in net loss, while the company also secured new financing to address debt and future growth.

Neuronetics saw a 12% increase in revenue and a reduction in net losses in the first quarter of 2024 compared to the same period last year.